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background: Dofetilide is indicated for pharmacological cardioversion and maintenance of sinus rhythm (SR) in patients with symptomatic atrial 
fibrillation or flutter. Though most patients achieve SR during the drug loading, there is no evidence to guide the most appropriate next clinical steps 
for those that fail both chemical and electrical cardioversion during the admission.
methods: We conducted a retrospective chart review of a cohort of 1,404 patients loaded on dofetilide therapy from 2008 to 2012. Seventy 
patients discharged from the hospital on dofetilide not in SR define the study cohort. Here we examine the ensuing clinical course and efficacy of 
continued dofetilide treatment following discharge.
results: The cohort’s atrial rhythms, follow-up outpatient DC cardioversion (DCC) history, DCC success rate, and dofetilide status at time of chart 
review are summarized in figure 1. Notably, 45.7% of patients successfully cardioverted or had improved symptoms after discharge without need for 
ablation (bold-underlined in fig. 1, mean treatment duration 1.1 +/- 1.3 years). Furthermore, 45.7% of the entire cohort was still on treatment at the 
time of chart review (bold-italicized in fig. 1, mean treatment duration 1.4 +/- 1.2 years), of whom 11 had undergone ablation.
 
conclusions: We observe a large subset of patients for whom continued outpatient dofetilide treatment is efficacious in achieving cardioversion 
and/or a reduction in symptoms, despite inability to sustain SR during drug loading.
